Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)

NCT01881230 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

191

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Tumor
Breast Cancer
Cancer of the Breast
Estrogen Receptor- Negative Breast Cancer
HER2- Negative Breast Cancer
Progesterone Receptor- Negative Breast Cancer
Recurrent Breast Cancer
Stage IV Breast Cancer
Triple-negative Breast Cancer
Triple-negative Metastatic Breast Cancer
Metastatic Breast Cancer

Interventions

DRUG: nab-Paclitaxel
DRUG: Carboplatin
DRUG: Gemcitabine

Sponsor

Celgene